Fertility and Ovarian Reserve in Female Childhood Cancer Survivors

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Oct 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain cancer treatments can affect the fertility and ovarian health of female survivors of childhood cancer. Specifically, it looks at the impact of low to moderate doses of a type of chemotherapy known as alkylating agents and whether a technique called ovarian cryopreservation (which freezes eggs to help preserve fertility) can help protect ovarian function. The goal is to find new ways to predict if these women might experience early ovarian failure, which can affect their ability to have children in the future.

To participate in this trial, women must be between the ages of 18 and 26, and they should have been diagnosed with cancer before turning 17. They must have received treatment at specific hospitals in Belgium and still be alive today. During the study, participants will undergo evaluations to assess their fertility and ovarian health. This research aims to improve the quality of life and fertility options for these survivors by developing better tools to predict and manage ovarian issues.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Child and adolescent female patients included in the Paediatrics Late Effects Project:
• • diagnosed with cancer1 between 01/01/2004 and 31/12/2018
• • \<17 years old at diagnosis
• • treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF
• • alive
• • ≥ 18 years-old at time of recruitment.
• Exclusion Criteria:
• • Cancer diagnosis for controls